Catalyst Pharmaceuticals (CPRX) Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.

Does the media favor RDY or CPRX?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Dr. Reddy's Laboratories and 10 mentions for Catalyst Pharmaceuticals. Dr. Reddy's Laboratories' average media sentiment score of 1.61 beat Catalyst Pharmaceuticals' score of 1.23 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	13 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Catalyst Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor RDY or CPRX?

Catalyst Pharmaceuticals received 182 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 75.11% of users gave Catalyst Pharmaceuticals an outperform vote while only 59.41% of users gave Dr. Reddy's Laboratories an outperform vote.

Company	Underperform	Outperform
Dr. Reddy's Laboratories	Outperform Votes 322 59.41%	Underperform Votes 220 40.59%
Catalyst Pharmaceuticals	Outperform Votes 504 75.11%	Underperform Votes 167 24.89%

Which has more risk and volatility, RDY or CPRX?

Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Which has better valuation & earnings, RDY or CPRX?

Dr. Reddy's Laboratories has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$325.54B	0.04	$668M	$0.66	21.89
Catalyst Pharmaceuticals	$534.65M	5.61	$71.41M	$1.57	15.65

Do analysts prefer RDY or CPRX?

Dr. Reddy's Laboratories currently has a consensus target price of $17.00, indicating a potential upside of 17.69%. Catalyst Pharmaceuticals has a consensus target price of $32.29, indicating a potential upside of 31.37%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Is RDY or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Dr. Reddy's Laboratories' net margin of 17.25%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	17.25%	17.87%	12.32%
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%

Do insiders and institutionals hold more shares of RDY or CPRX?

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Dr. Reddy's Laboratories on 14 of the 19 factors compared between the two stocks.